Switching From Semaglutide to Tirzepatide

Medically reviewed by Amber Patel, MD · Last updated July 15, 2026. Nouri content is reviewed by licensed clinicians and updated as guidance changes.

Can you switch from semaglutide to tirzepatide?

Yes, and it's a common move — but it's a genuine medication change, not a dose swap. Semaglutide is a GLP-1 receptor agonist; tirzepatide is a dual GIP/GLP-1 receptor agonist. They act on different receptors with different potency, which is why there's no equivalence table that says "your semaglutide dose equals this tirzepatide dose." When you switch, you begin tirzepatide at its FDA-labeled starting dose of 2.5 mg once weekly and follow its own titration ladder (2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg, at least four weeks per step), even if you'd worked all the way up to the maximum semaglutide dose. Our tirzepatide dosing chart lays out that full schedule.

Do you need to wean off semaglutide first?

No lengthy washout is needed. Both medications are once-weekly, so the practical approach — under your prescriber's guidance — is to take your last semaglutide dose, then take the first tirzepatide dose about a week later, on what would have been your next semaglutide injection day. That keeps the weekly rhythm uninterrupted without overlapping the two drugs. There's no need to taper semaglutide down first; you simply stop it and start tirzepatide at 2.5 mg. Your prescriber may fine-tune the timing based on your history.

Why do people switch from semaglutide to tirzepatide?

The most common reasons are a weight-loss plateau, wanting greater results, or side-effect tolerability. The clearest evidence comes from SURMOUNT-5, a head-to-head trial published in 2025: over 72 weeks, adults on tirzepatide lost on average 20.2% of body weight versus 13.7% on semaglutide, and fewer people discontinued tirzepatide for GI side effects (2.7% vs 5.6%). Those are results for the branded molecules studied in the trial — not for compounded versions, which aren't FDA-approved or shown to be equivalent, and individual results vary. Still, the data is why many people who stall on semaglutide ask about tirzepatide. For a fuller side-by-side, see our comparison of compounded semaglutide vs tirzepatide.

Will the side effects come back when I switch?

They can, briefly. Because tirzepatide starts at 2.5 mg and climbs its own escalation schedule, the GI effects that cluster around dose increases — nausea, mostly — often return for the first few weeks as your body re-adapts, then ease at a steady dose. That reset is by design: the low starting dose exists to rebuild tolerance. It's usually milder than a first-ever GLP-1 start, since you've already been on a related medication, but plan for a short adjustment period rather than a seamless handoff. Our guide to tirzepatide side effects covers what to expect and how to manage it.

Will I regain weight during the switch?

A brief switch done under prescriber guidance — last semaglutide dose, then tirzepatide about a week later — doesn't leave a long untreated gap, so it's not the same as stopping GLP-1 treatment altogether. The bigger driver of lasting results isn't which molecule you're on week to week; it's the habits, nutrition, and support around the medication. That's the part a complete program is built to hold steady through a transition, which is why the switch is worth planning with your care team rather than doing on your own.

How switching works with a Nouri prescription

At Nouri, changing molecules is a clinical conversation, not a checkout change. A U.S.-licensed physician reviews whether tirzepatide is appropriate for you, sets the starting dose and timing, and your Care Team handles the transition by message — and because every dose is the same price, moving from semaglutide to tirzepatide is a medical decision with no billing surprise. If you're exploring the switch, our page on tirzepatide telehealth explains the ongoing-care model, and if you're newer to the process, how to get semaglutide online walks through intake to delivery.

Frequently asked questions

Can you switch directly from semaglutide to tirzepatide?

Yes, under prescriber guidance. You stop semaglutide and start tirzepatide at its own initiation dose of 2.5 mg once weekly — there's no mg-for-mg conversion because they're different molecules.

Do you need to wait between semaglutide and tirzepatide?

There's no long washout. Since both are once-weekly, most people take the first tirzepatide dose about a week after the last semaglutide dose, on the usual injection day, so the weekly cadence isn't interrupted.

What dose of tirzepatide do you start on after semaglutide?

2.5 mg once weekly — tirzepatide's standard starting dose — regardless of the semaglutide dose you finished on. From there it titrates up in 2.5 mg steps, at least four weeks apart.

Is tirzepatide better than semaglutide for weight loss?

In the SURMOUNT-5 head-to-head trial, tirzepatide produced greater average weight loss (20.2% vs 13.7% over 72 weeks) with fewer GI-related discontinuations. Those are trial results for the branded molecules; individual results vary, and the right choice depends on your health and your prescriber's judgment.

Will I regain weight when switching from semaglutide to tirzepatide?

A short, prescriber-guided switch doesn't create a long untreated gap, so it's different from stopping treatment. Lasting results depend most on the nutrition, habits, and support around the medication — worth keeping steady through the transition.

Sources

• Ozempic (semaglutide) Prescribing Information — DailyMed. dailymed.nlm.nih.gov
• Mounjaro (tirzepatide) Prescribing Information — DailyMed. dailymed.nlm.nih.gov
• Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). NEJM 2025. nejm.org
• Zepbound (tirzepatide) Prescribing Information — Dosage — DailyMed. dailymed.nlm.nih.gov
• Wegovy (semaglutide) Prescribing Information — DailyMed. dailymed.nlm.nih.gov
• FDA — FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. fda.gov

Considering a switch? See if you qualify with Nouri — a U.S.-licensed physician reviews your history and current dose, so there's no guesswork in the transition. One price, the same at any dose.

Compounded semaglutide and tirzepatide are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness, or quality, and are not therapeutically equivalent to Wegovy, Ozempic, Zepbound, or Mounjaro. Trial results cited are for the branded molecules studied; individual results vary. This article is educational, not medical advice. Nouri connects patients with licensed, independent physicians who make all prescribing and switching decisions.